Pacific Biosciences of California PACB Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $2.01M-27.5% | $2.77M-7.7% | $3M-36.1% | $4.7M+9.4% | $4.29M+5.6% | ||
| -$8.28M+79.5% | -$40.37M-6.2% | -$38M+9.4% | -$41.93M+90.2% | -$426.08M— | ||
| -$5.14M+86.3% | -$37.44M-5.8% | -$35.4M+14.0% | -$41.18M+28.3% | -$57.41M+59.9% | ||
| -$8.36M+79.7% | -$41.2M-6.0% | -$38.88M+13.3% | -$44.85M+89.5% | -$428.93M-180% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Pacific Biosciences of California's revenue?
- Pacific Biosciences of California (PACB) generated $160.0M in revenue over the trailing twelve months, up 5.0% year over year.
- Is Pacific Biosciences of California profitable?
- Pacific Biosciences of California is not currently profitable: it reported a net loss of $128.6M over the trailing twelve months, a -80.3% net margin.
- What are Pacific Biosciences of California's profit margins?
- Gross margin is 37.5% and operating margin is -83.3%, with a -80.3% net margin.
- What is Pacific Biosciences of California's earnings per share?
- Pacific Biosciences of California's diluted EPS over the trailing twelve months is $-0.43.
- Where does Pacific Biosciences of California's income statement data come from?
- Every line is extracted from Pacific Biosciences of California's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
